7. Immunostimulatory CpG Oligodeoxynucleotides as Vaccine Adjuvants

  1. Manmohan Singh M. Pharm., Ph.D.
  1. Dennis M. Klinman,
  2. Debbie Currie and
  3. Hidekazu Shirota

Published Online: 2 NOV 2006

DOI: 10.1002/9780470134931.ch7

Vaccine Adjuvants and Delivery Systems

Vaccine Adjuvants and Delivery Systems

How to Cite

Klinman, D. M., Currie, D. and Shirota, H. (2007) Immunostimulatory CpG Oligodeoxynucleotides as Vaccine Adjuvants, in Vaccine Adjuvants and Delivery Systems (ed M. Singh), John Wiley & Sons, Inc., Hoboken, NJ, USA. doi: 10.1002/9780470134931.ch7

Editor Information

  1. Novartis Vaccines, Emeryville, California, USA

Author Information

  1. Laboratory of Experimental Immunology, National Cancer Institute, Frederick, Maryland, USA

  1. The assertions herein are those of the authors and are not to be construed as official or as reflecting the views of the U.S. Food and Drug Administration at large.

Publication History

  1. Published Online: 2 NOV 2006
  2. Published Print: 15 JUN 2007

ISBN Information

Print ISBN: 9780471739074

Online ISBN: 9780470134931

SEARCH

Keywords:

  • immunostimulatory CpG oligodeoxynucleotides;
  • CpG ODNs augmenting immune response;
  • cell surface receptor and uptake of D-class CpG ODNs

Summary

This chapter contains sections titled:

  • Introduction

  • Immunomodulatory Properties of CpG ODNs

  • CpG ODNs as Vaccine Adjuvants

  • CpG ODNs Improve the Response to Mucosal Vaccines

  • CpG ODNs Augment the Immune Response of Immunocompromized Animals

  • Adjuvant Activity of CpG ODNs in Nonhuman Primates

  • Human Clinical Experience

  • CpG ODN Safety

  • Summary

  • Future Prospects

  • References